Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 5/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039798 | 1.00 | KDM4E (0.36) | KDM4EL3MBTL1POLBALDH1A1HPGD | |
| SCHEMBL3577441 | 0.86 | ALDH1A1 (0.35) | KDM4EL3MBTL1POLBALDH1A1HPGD | |
| SCHEMBL3586182 | 0.78 | MAPT (0.39) | KDM4EL3MBTL1POLBALDH1A1HPGD | |
| SCHEMBL5636179 | 0.75 | KDM4D (0.33) | KDM4EALDH1A1HPGDMAOBMAOA | |
| SCHEMBL5260297 | 0.75 | KDM4D (0.33) | KDM4EALDH1A1HPGDMAOBMAOA | |
| SCHEMBL3571183 | 0.74 | MAPT (0.43) | KDM4EL3MBTL1POLBALDH1A1HPGD | |
| SCHEMBL3581122 | 0.72 | PLAU (0.43) | MAPTMAOBKDM1ARET | |
| SCHEMBL3581119 | 0.72 | PLAU (0.43) | MAPTMAOBKDM1ARET | |
| SCHEMBL3577434 | 0.68 | PLAU (0.44) | ALDH1A1MAOBKDM1A | |
| SCHEMBL3577439 | 0.68 | PLAU (0.44) | ALDH1A1MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | KDM4E 3723/4885L3MBTL1 797/4885POLB 1252/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KDM4E 4273/4885L3MBTL1 495/4885POLB 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.